EPF Acknowledgement of Financial Support in 2022
Funding Transparency (Jan - Dec 2022)
|
Overall proportion of Industry and non-industry income |
Private: 66,00% Public: 34,00 % |
|
Percentage of the highest contribution from a single Industry Donor |
EFPIA 3.16% |
|
Percentage of the highest contribution from a single Industry Company |
Novartis 4.22% |
| Public Contribution 2022 | % of total income | |
| TOTAL European Commission support to projects 2022 | €701,899.48 | |
| Core MD | €6,904.96 | 0.3% |
| ComparEU | €191,885.64 | 8.1% |
| EATRIS + | €23,638.11 | 1.0% |
| EHDEN | €28,185.05 | 1.2% |
| EU-PEARL | €127,425.69 | 5.4% |
| Gravitate Health | €51,116.39 | 2.2% |
| H2O | €68,515.78 | 2.9% |
| HTA | €11,455.46 | 0.5% |
| IMMUCAN | €18,718.44 | 0.8% |
| IMMUNIVERSE | €946.03 | 0.0% |
| LABEL To ENABLE | €19,900.00 | 0.8% |
| Pharmaledger | €79,505.33 | 3.4% |
| PERISCOPE | €30,353.56 | 1.3% |
| PERMIT | €31,785.78 | 1.3% |
| PREFER | €6,051.31 | 0.3% |
| PROPHET | €5,511.95 | 0.2% |
| Contribution to Operations | % of total income | |
| Operational & Engagement - work plan 2022/ Project Development 2022 | €769,902.24 | |
| Abbvie | €35,000.00 | 1.5% |
| Amgen | €35,000.00 | 1.5% |
| Astellas Pharma Europe Ltd | €30,000.00 | 1.3% |
| BMS | €50,000.00 | 2.1% |
| Baxter | €15,000.00 | 0.6% |
| CSL | €10,000.00 | 0.4% |
| Chiesi | €25,000.00 | 1.1% |
| Edwards | €25,000.00 | 1.1% |
| GSK | €30,000.00 | 1.3% |
| Horizon Therapeutics | €35,000.00 | 1.5% |
| Janssen | €50,000.00 | 2.1% |
| Medicines for Europe | €20,000.00 | 0.8% |
| MSD | €56,902.24 | 2.4% |
| Merck | €40,000.00 | 1.7% |
| Novartis | €100,000.00 | 4.2% |
| Pfizer | €25,000.00 | 1.1% |
| Philips | €10,000.00 | 0.4% |
| Roche | €60,000.00 | 2.5% |
| Sanofi-Aventis | €50,000.00 | 2.1% |
| UCB | €25,000.00 | 1.1% |
| Reclassification | €43,000.00 | |
| Membership | €23,300.00 | 1.0% |
| Capacity Building Programme 2022 - DSL - PEOF -Artificial Intelligence | €497,010.00 | |
| Contribution to the CBP and others | % of total income | |
| EFPIA | €75,000.00 | 3.2% |
| European Digitial Health Academy | €37,010.00 | 1.6% |
| Galapagos | €33,000.00 | 1.4% |
| Gilead | €20,000.00 | 0.8% |
| GSK | €30,000.00 | 1.3% |
| Horizon Therapeutics | €40,000.00 | 1.7% |
| IQVIA | €10,000.00 | 0.4% |
| MedTech Europe | €10,000.00 | 0.4% |
| MSD | €30,000.00 | 1.3% |
| NEF AI Fund | €51,000.00 | 2.2% |
| NEF AI Fund | €15,000.00 | 0.6% |
| Novavax | €15,000.00 | 0.6% |
| Novo Nordisk | €26,000.00 | 1.1% |
| Roche | €40,000.00 | 1.7% |
| Servier | €20,000.00 | 0.8% |
| Takeda | €35,000.00 | 1.5% |
| Reclassification | €10,000.00 | |
| Congress 2022 | €374,535.18 | |
| Contribution to CGS | % of total income | |
| Congress carry forward from 2021 | €269,035.18 | 11.4% |
| Boston Scientific | €20,000.00 | 0.8% |
| BridgeBio | €5,000.00 | 0.2% |
| Grunenthal | €5,000.00 | 0.2% |
| MedTech Europe | €9,000.00 | 0.4% |
| Mindview | €150.00 | 0.0% |
| Novavax | €20,000.00 | 0.8% |
| Roche | €15,000.00 | 0.6% |
| Takeda | €30,000.00 | 1.3% |
| Reclassification | €1,350.00 | |
| Other income (including reserves) | €14,966.75 | |
| % of total income | ||
| Other Income | €14,966.75 | 0.6% |
| Total Income | €2,358,313.65 | |
| Accrual and deferals | €12,593.35 | |
| Total Income net of adjustments | €2,370,907.00 |